Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ionis Pharmaceuticals
(NQ:
IONS
)
49.90
+0.65 (+1.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,306,084
Open
49.40
Bid (Size)
49.90 (1)
Ask (Size)
49.91 (43)
Prev. Close
49.25
Today's Range
49.03 - 50.37
52wk Range
35.95 - 54.44
Shares Outstanding
141,797,854
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals
August 26, 2024
Via
Benzinga
12 Analysts Have This To Say About Ionis Pharmaceuticals
August 02, 2024
Via
Benzinga
Performance
YTD
-5.62%
-5.62%
1 Month
-0.68%
-0.68%
3 Month
+36.90%
+36.90%
6 Month
+7.22%
+7.22%
1 Year
+21.53%
+21.53%
More News
Read More
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
July 22, 2024
Via
Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
July 22, 2024
Via
Investor's Business Daily
The Latest Analyst Ratings For Ionis Pharmaceuticals
July 16, 2024
Via
Benzinga
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
June 27, 2024
Via
Benzinga
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
June 03, 2024
Via
Benzinga
The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals
May 08, 2024
Via
Benzinga
The Latest Analyst Ratings For Ionis Pharmaceuticals
April 09, 2024
Via
Benzinga
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
June 24, 2024
Via
Benzinga
Masters In Trading - Saturday, June 22
June 22, 2024
Via
Talk Markets
Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile
May 31, 2024
Via
Benzinga
Exposures
Product Safety
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
May 31, 2024
Via
Benzinga
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
May 16, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals
February 22, 2024
Via
Benzinga
Earnings Scheduled For February 21, 2024
February 21, 2024
Via
Benzinga
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16, 2024
From
Biogen Inc.
Via
GlobeNewswire
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
May 09, 2024
Via
InvestorPlace
IONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows
March 13, 2024
Via
Benzinga
Are These 5 Undervalued Stocks Ready to Break Out?
March 08, 2024
Via
MarketBeat
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
March 06, 2024
From
Biogen Inc.
Via
GlobeNewswire
JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know
February 01, 2024
Via
Benzinga
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
January 31, 2024
Via
Benzinga
Exposures
Product Safety
Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study
January 22, 2024
Via
Benzinga
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.